MET and colorectal carcinoma: In recent years, several evidence have defined the WT RAS CRC subgroup as a highly heterogeneous population characterized by various gene alterations as fusions (e.g. BRAF; FGFR, NTRK, ALK, RET, ROS1), microsatellite instability (MSI), amplifications (e.g. HER2, MET), and mutations (e.g. PI3KCA, PTEN, AKT) (33–35).